(医药健闻 2026年02月03日讯) CRDMO药明生物宣布,已与Vertex Pharmaceuticals Incorporated签署一项针对创新三特异性T细胞衔接子(TCE)的授权和研究服务协议,该TCE用于治疗B细胞介导的自身免疫性疾病。根据协议,Vertex拥有该处于临床前阶段的创新三特异性TCE的全球独家开发和商业化权利。药明生物将获得首付款,并有资格获得开发、监管和销售里程碑付款...
Source Link(医药健闻 2026年02月03日讯) CRDMO药明生物宣布,已与Vertex Pharmaceuticals Incorporated签署一项针对创新三特异性T细胞衔接子(TCE)的授权和研究服务协议,该TCE用于治疗B细胞介导的自身免疫性疾病。根据协议,Vertex拥有该处于临床前阶段的创新三特异性TCE的全球独家开发和商业化权利。药明生物将获得首付款,并有资格获得开发、监管和销售里程碑付款...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.